Johannes H Schulte
Overview
Explore the profile of Johannes H Schulte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
164
Citations
5603
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diarra Y, Brockmeyer C, Fischhuber K, Hulsenbeck I, Ting S, Reschke M, et al.
EJC Paediatr Oncol
. 2025 Mar;
1:None.
PMID: 40061040
Introduction: Advanced localized retinoblastoma can be cured by enucleation, but extraocular spread of retinoblastoma cells is associated with a high mortality. Risk-stratified adjuvant treatment with chemotherapy and radiotherapy has been...
2.
Mascarenhas L, Dubois S, Albert C, Bielack S, Orbach D, Federman N, et al.
J Clin Oncol
. 2025 Mar;
:JCO2500353.
PMID: 40030088
No abstract available.
3.
Launspach M, Mindermann A, Schulz J, Alasfar L, Cyrull S, Zirngibl F, et al.
United European Gastroenterol J
. 2025 Feb;
PMID: 39955611
Exocrine pancreatic insufficiency (EPI) is suspected but remains understudied in immunosuppressed conditions such as post-hematopoietic stem cell transplantation (HSCT). This prospective observational study aimed to investigate the incidence, impact, and...
4.
Mascarenhas L, Dubois S, Albert C, Bielack S, Orbach D, Federman N, et al.
J Clin Oncol
. 2025 Feb;
43(8):1046.
PMID: 39951654
No abstract available.
5.
Mascarenhas L, Dubois S, Albert C, Bielack S, Orbach D, Federman N, et al.
J Clin Oncol
. 2025 Jan;
:JCO2400848.
PMID: 39869835
Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with efficacy in children with TRK fusion tumors. We evaluated patient outcomes after elective discontinuation of larotrectinib in the absence...
6.
Grunewald L, Andersch L, Helmsauer K, Schwiebert S, Klaus A, Henssen A, et al.
Pharmacol Res
. 2025 Jan;
212:107608.
PMID: 39828101
Current treatment protocols have limited success against MYCN-amplified neuroblastoma. Adoptive T cell therapy presents an innovative strategy to improve cure rates. However, L1CAM-targeting CAR T cells achieved only limited response...
7.
Flaadt T, Rehm J, Simon T, Hero B, Ladenstein R, Lode H, et al.
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796776
Background: The incorporation of anti-GD2 antibodies such as ch14.18/SP2/0 into the multimodal treatment of high-risk neuroblastoma (HR-NB) patients has improved their outcomes. As studies assessing the long-term outcomes, long-term sequelae,...
8.
Zirngibl F, Gebert P, Materne B, Launspach M, Kunkele A, Hundsdoerfer P, et al.
Transplant Cell Ther
. 2025 Jan;
PMID: 39788293
Hematopoietic stem cell transplantation (HSCT) serves as a therapeutic intervention for various pediatric diseases. Acute and chronic graft-versus-host disease (GVHD) are decisive determinants of successful allogeneic HSCT. The immunosuppressive agent...
9.
Hollander J, Szymansky A, Wunschel J, Astrahantseff K, Rosswog C, Thorwarth A, et al.
Cancer Res Commun
. 2025 Jan;
5(1):167-177.
PMID: 39760332
Real-time molecular monitoring of TERT-rearranged high-risk neuroblastoma is an unmet clinical need. We tested liquid biopsy-based assays for patient-individualized TERT breakpoint sequences to monitor disease in pediatric patients. Our digital...
10.
Burkert M, Blanc E, Thiessen N, Weber C, Toedling J, Monti R, et al.
iScience
. 2024 Dec;
27(10):110918.
PMID: 39635126
Telomere maintenance in neuroblastoma is linked to poor outcome and caused by either telomerase reverse transcriptase (TERT) activation or through alternative lengthening of telomeres (ALT). In contrast to TERT activation,...